Phase III trial of BC 819 in patients with bladder cancer that was resistant to initial treatment with BCG.

Trial Profile

Phase III trial of BC 819 in patients with bladder cancer that was resistant to initial treatment with BCG.

Planning
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs BC 819 (Primary)
  • Indications Bladder cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms BCG Refractory
  • Sponsors BioCancell Therapeutics
  • Most Recent Events

    • 14 Aug 2017 This trial will be performed under a Special Protocol Assessment provision of the US FDA, as reported in a BioCancell Therapeutics media release
    • 14 Aug 2017 According to a BioCancell Therapeutics media release, this trial is expected to be initiated in 2017.
    • 10 Sep 2015 Planned initiation date changed from 1 Dec 2015 to 1 Jan 2016 according to a BioCancell Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top